In patients with COPD, therapy with tiotropium was associated with improvements in lung function, quality of life, and exacerbations during a 4-year period but did not significantly reduce the rate of decline in FEV(1). (ClinicalTrials.gov number, NCT00144339.)
No takes yet. Share an insight, caveat, or question.
Tashkin et al. (2008) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: